Table I.
Characteristics of the study population
| All patients | Patients included in statistical analysis | |
|---|---|---|
| Number | n = 19 | n = 10* |
| Sex: M:F | 8:11 | 6:4 |
| Age, years, median (IQR) | 58 (45–74) | 66.5 (56–77) |
| Number of previous treatments, median (IQR) | 5 (3–7) | 5 (4–7) |
| Previous treatments, n (%) | ||
| Topical corticosteroids | 19 (100) | 10 (100) |
| Phototherapy (PUVA, UVB, and/or UVB TL01) | 13 (68) | 6 (60) |
| Methotrexate | 14 (74) | 7 (70) |
| Cyclosporine | 6 (32) | 3 (30) |
| Other | 15 (79)** | 8 (80) |
| Atopic dermatitis, n (%) | 7 (37) | 5 (50) |
| Asthma/rhinitis, n (%) | 6 (32) | 2 (20) |
| Number of lesions at baseline (n)*** | 14 | 9 |
| > 50, n (%) | 10 (71) | 6 (67) |
| 10–50, n (%) | 3 (21) | 3 (33) |
| < 10, n (%) | 1 (7) | 0 |
*
Patients with values at baseline AND at follow-up after 1–3 months on treatment with dupilumab.
**
Antihistamines (n = 12), gabapentin (n = 5), pregabalin (n = 4), antidepressives (n = 4), omalizumab (n = 2), systemic corticosteroids (n = 2), apremilast (n = 1), lymecycline (n = 1), naltrexone (n = 1), aprepitant (n = 1).
***
Clinical pictures missing for 5 of the patients at the start of treatment.
IQR: interquartile range; PUVA: psoralen plus ultraviolet A; UVB: ultraviolet B.